Receptor for Advanced Glycation End Products is Involved in Platelet Hyperactivation and Arterial Thrombosis during Chronic Kidney Disease
- PMID: 32726852
- DOI: 10.1055/s-0040-1714101
Receptor for Advanced Glycation End Products is Involved in Platelet Hyperactivation and Arterial Thrombosis during Chronic Kidney Disease
Abstract
Background: Chronic kidney disease (CKD) is associated with a high cardiovascular mortality due to increased rates of vascular lesions and thrombotic events, as well as serum accumulation of uremic toxins. A subgroup of these toxins (advanced glycation end products [AGEs] and S100 proteins) can interact with the receptor for AGEs (RAGE). In this study, we analyzed the impact of CKD on platelet function and arterial thrombosis, and the potential role of RAGE in this process.
Methods: Twelve weeks after induction of CKD in mice, platelet function and time to complete carotid artery occlusion were analyzed in four groups of animals (sham-operated, CKD, apolipoprotein E [Apoe]-/-, and Apoe-/-/Ager-/- mice).
Results: Analysis of platelet function from whole blood and platelet-rich plasma showed hyperactivation of platelets only in CKD Apoe-/- mice. There was no difference when experiments were done on washed platelets. However, preincubation of such platelets with AGEs or S100 proteins induced RAGE-mediated platelet hyperactivation. In vivo, CKD significantly reduced carotid occlusion times of Apoe-/- mice (9.2 ± 1.1 vs. 11.1 ± 0.6 minutes for sham, p < 0.01). In contrast, CKD had no effect on occlusion times in Apoe-/-/Ager-/- mice. Moreover, carotid occlusion in Apoe-/- CKD mice occurred significantly faster than in Apoe-/-/Ager-/- CKD mice (p < 0.0001).
Conclusion: Our results show that CKD induces platelet hyperactivation, accelerates thrombus formation in a murine model of arterial thrombosis, and that RAGE deletion has a protective role. We propose that RAGE ligands binding to RAGE is involved in CKD-induced arterial thrombosis.
Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
None declared.
Similar articles
-
Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression.Nephrol Dial Transplant. 2019 Dec 1;34(12):2018-2030. doi: 10.1093/ndt/gfz012. Nephrol Dial Transplant. 2019. PMID: 30778553
-
Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis.Arterioscler Thromb Vasc Biol. 2016 May;36(5):800-9. doi: 10.1161/ATVBAHA.115.306349. Epub 2016 Mar 17. Arterioscler Thromb Vasc Biol. 2016. PMID: 26988587
-
Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.Inflamm Cell Signal. 2014;1(5):e279. doi: 10.14800/ics.279. Inflamm Cell Signal. 2014. PMID: 26082935 Free PMC article.
-
Role of multiligand/RAGE axis in platelet activation.Thromb Res. 2014 Mar;133(3):308-14. doi: 10.1016/j.thromres.2013.11.007. Epub 2013 Nov 16. Thromb Res. 2014. PMID: 24296115 Review.
-
Uremic Toxicity of Advanced Glycation End Products in CKD.J Am Soc Nephrol. 2016 Feb;27(2):354-70. doi: 10.1681/ASN.2014101047. Epub 2015 Aug 26. J Am Soc Nephrol. 2016. PMID: 26311460 Free PMC article. Review.
LinkOut - more resources
-
Full Text Sources
-
Miscellaneous